PRL3

Originally aimed at tumours, a new antibody treatment also offers a safer alternative to eye injections for neovascular eye diseases.

Clinical trial results show a new antibody drug with an unconventional approach extends survival for patients with various aggressive cancers.

In times of stress, cancer cells move a protein normally found inside the cell to the cell surface, making it accessible to antibodies for immunotherapy.